Comparing PD-L1 with PD-1 antibodies combined with lenvatinib and hepatic arterial infusion chemotherapy for unresectable hepatocellular carcinoma
PD-L1 antibody appears to be a preferable companion in the combination therapy of HAIC + ICIs + lenvatinib compared to PD-1 antibody, showing higher ORR and relatively lower incidence of severe AEs. Further prospective studies involving a larger patient population are warranted.
Authors
- Jibin Li (ORCID: https://orcid.org/0000-0001-7632-3648)
- Qiaoxuan Wang
- Rongping Guo
- Jing Zhou (ORCID: https://orcid.org/0000-0001-6601-4446)
- Lie Zheng (ORCID: https://orcid.org/0000-0002-8405-2988)
- Wei Wei (ORCID: https://orcid.org/0000-0001-5929-7409)
- Shaohua Li
- Rongce Zhao
- Lianghe Lu (ORCID: https://orcid.org/0000-0002-2860-6093)
- Jie Mei (ORCID: https://orcid.org/0000-0002-5676-4216)
Institutions
- Sun Yat-sen University (CN)
- Sun Yat-sen University Cancer Center (CN)
- State Key Laboratory of Oncology in South China
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2024-10-23
- DOI
- https://doi.org/10.3389/fimmu.2024.1491857
- Citations
- 2
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.74
Funders
- National Natural Science Foundation of China
- Sun Yat-sen University